drugset / Trial / NCT00799747

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

NCT00799747

Phase 1 Completed 56 enrolled AstraZeneca
RandomizedSingle-groupSingle-blind

Summary

The primary aim of this study is to investigate the safety and tolerabilty of AZD4017 when given as single oral ascending doses to Japanese healthy male volunters. This will be done by comparing the effect of AZD4017 to placebo. The study will aslo investigate the absorption, distrubution and disappearance of AZD4017 in the body. Information about plasma concentrations of AZD4017 vs time after dose intake will also be collected. The future indication for AZD4017 is planned to be Type 2 Diabetes Mellitus.

Timeline

Start
2008-12
Primary completion
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4017 Small molecule 2 mg Oral

Indications

No indication recorded.